This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

22 Aug 2019

CPC’s GMP Manufacturing Facility Passes German Inspection

Chinese Peptide Company, a public Hangzhou-based CDMO (Stock Symbol: 002390) is pleased to announce that our GMP manufacturing facility has successfully passed its inspection by the competent authority of Germany as an“active substance manufacturer that has been inspected in accordance with Art. 111 (1) Directive 2001/83/EC transposed in the following national legislation: Sect 64 para 1 Arzneimittelgesetz (German Drug Law).

The GMP inspection was carried out in order to clear CPC to develop and manufacture a specific NCE for an undisclosed European biopharmaceutical partner.

Comment from Shawn Lee, CEO and Founder of Chinese Peptide Company.

“We are very pleased with the positive EMA inspection results as this marks an important milestone for CPC groups and its quality program. In addition to the inspection by the European Medicines Agency and German authority, CPC has also been inspected by the United States (FDA), Korea (MFDS) and China (NMPA). This inspection also establishes CPC as a central player in the European peptide API markets – for new chemical entities (NCEs) and generic peptide APIs and emerging markets across the globe.”

Mentioned Companies
Chinese Peptide Co
View company profile
Related categories
Generic Peptides Generic APIs